Condition
Mesial Temporal Lobe Epilepsy
Total Trials
6
Recruiting
3
Active
3
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (4)
P 1 (1)
P 3 (1)
Trial Status
Recruiting3
Terminated1
Enrolling By Invitation1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05608408Not ApplicableRecruitingPrimary
PRIME: PReservIng Memory in Epilepsy
NCT05135091Phase 3RecruitingPrimary
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
NCT06063850Phase 1RecruitingPrimary
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06521437Not ApplicableEnrolling By InvitationPrimary
Hippocampal Network Function in Epilepsy
NCT04710004Not ApplicableTerminatedPrimary
Electrophysiological Biomarkers in MTLE Patients.
NCT02383407Not ApplicableCompletedPrimary
Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
Showing all 6 trials